Bloomberg News
@Bloomberg-News·2.8M subscribers·40.1K videos
NIH: Halted Vaccine Study Shows 'No Compromises' on Safety
Posted
September 9, 2020
Views
513
Likes
11
Comments
4
Engagement
2.92%
September 9, 2020
513
11
4
2.92%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Episode Timeline
Every episode in order around the one you’re watching — click any card and the page flips straight to it.
1:55Now PlayingAstraZeneca's suspension of final testing of its potential COVID-19 vaccine while it investigates a volunteer's illness shows there will be “no compromises” on safety in developing the shots, the chief of the National Institutes of Health told Congress on Wednesday.
“This ought to be reassuring,” NIH Director Dr. Francis Collins said before a Senate committee. “When we say we are going to focus first on safety and make no compromises, here is Exhibit A of how that is happening in practice.”
Late Tuesday, AstraZeneca announced its final-stage studies are on temporary hold while the company looks into whether a test subject's illness is a side effect of the shot or a coincidence. The company gave no details on the illness, but Collins said it involved a “spinal cord problem.”
Behind-the-scenes monitors known as the “data and safety monitoring board” in Britain paused vaccinations while alerting its safety counterparts in the U.S., said Dr. Moncef Slaoui of Operation Warp Speed, the Trump administration’s vaccine development program.
Late last month, AstraZeneca began recruiting 30,000 people in the U.S. for its largest study of the vaccine. It also is testing the vaccine, developed by Oxford University, in thousands of people in Britain and in smaller studies in Brazil and South Africa.
AstraZeneca said the pause in vaccinations covers studies in the U.S. and other countries.
Scientists around the world have been scrambling to develop a vaccine against the coronavirus since the outbreak began. Nearly 900,000 deaths have been reported in the pandemic.
The company's announcement comes amid worries that President Donald Trump will pressure the U.S. Food and Drug Administration to approve a vaccine before it’s proven to be safe and effective.
Collins said Wednesday that the decision will be based on science alone and that he will roll up his sleeve to get vaccinated once that happens.
It's not uncommon for pauses in research to investigate if an unexpected health complaint is really related to a vaccine or not, he told senators worried about what the AstraZeneca suspension means for that year-end goal.
“The reason we're investing not in one but six different vaccines is because of the expectation that they won't all work,” Collins said.
Subscribe to our YouTube channel
QUICKTAKE ON SOCIAL:
Follow QuickTake on Twitter: twitter.com/quicktake
Like QuickTake on Facebook: facebook.com/quicktake
Follow QuickTake on Instagram: instagram.com/quicktake
Subscribe to our newsletter
Email us at quicktakenews@gmail.com
QuickTake by Bloomberg is a global news network delivering up-to-the-minute analysis on the biggest news, trends and ideas for a new generation of leaders.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
